Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2008

View Archived Issues

Insights into the mechanism of action of maspin

Novel compounds for gastrointestinal disorders revealed in recent patents

Recent Daiichi Sankyo patents impart new coagulation factor Xa inhibitors

Novel agents for rheumatoid arthritis disclosed in recent patent literature

Non-brain-penetrant CB1 antagonists reduce weight in vivo

CRADA extension for BioDiem's live attenuated influenza vaccine program

Amorfix shows efficacy of DSE monoclonal antibodies in ASL mouse model

Lorus Therapeutics rounds up Q1 developments

ACE-031 begins phase I testing for loss of muscle

Peplin completes acquisition of Neosil for USD 6.7 million in an all-stock transaction

Pipex Pharmaceuticals changes name to Adeona Pharmaceuticals

FDA issues complete response to AMAG's NDA for ferumoxytol

FDA puts back PDUFA date for Takeda's TAK-390MR NDA by three months

Daiichi Sankyo acquires 52.5% of the equity share capital of Ranbaxy for USD 736 million

Peregrine completes enrollment in first stage of phase II trial of bavituximab in NSCLC

Biotec Pharmacon presents update on development of SBG

Archemix and Lilly sign agreement for R&D and intellectual property in aptamers

4SC reports results from phase I trial with cancer drug candidate 4SC-201

Avigen's AV-650 did not meet efficacy endpoints in phase IIb MS trial

Discovery submits complete response to May 2008 FDA approvable letter for Surfaxin

Raptor initiates patient dosing in phase IIa clinical trial of cysteamine in NASH

GeoVax ships DNA and MVA vaccines to HVTN for phase IIa human clinical trial

Novartis is to acquire pulmonary business from Nektar for USD 115 million

Gastrointestinal prokinetic 5-HT4 receptor agonist DA-6566 described

UPLIFT study reveals long-term effects of tiotropium in COPD patients

Saiko-keishi-to relieves pain in patients with classical trigeminal neuralgia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.